S-1: AAQL Registers 4.28M Shares for Resale Amidst Growth & Losses

Antiaging Quantum Living Inc. registers 4.28 million Class A Common Stock shares for resale by selling stockholders, following debt conversion, as it expands PRC operations despite recurring losses and going concern doubts.

Summary

• Antiaging Quantum Living Inc. (AAQL) is registering 4,280,342 shares of Class A Common Stock for resale by selling stockholders.
• These shares were issued on November 25, 2025, upon the automatic conversion of amended promissory notes at a fixed price of $0.30 per share.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders.
• AAQL operates an online advertising business in New York and has expanded into technical development, platform maintenance, distributor support, and non-medical health management services in the Asia-Pacific and Chinese markets through its Dao Ling Doctor subsidiaries.
• For the six months ended September 30, 2025, revenue increased by 81.64% to $681,602, and net loss decreased by 52.64% to $(194,970) compared to the same period in 2024.
• For the year ended March 31, 2025, revenue significantly increased by 10806.76% to $817,898, primarily due to the new PRC technical operation support and maintenance services, but net loss increased by 74.45% to $(720,409).
• The company has an accumulated deficit of $1,604,682 and working capital of $23,279 as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• 100% of the company's revenue and accounts receivable for the six months ended September 30, 2025, were derived from a single customer, indicating significant concentration risk.
• The company has limited insurance coverage, including no D&O or key-man life insurance.

Sentiment

Score: 3

Explanation: While the company shows significant revenue growth from its new PRC operations and a reduction in net loss for recent interim periods, the overall financial health remains weak with recurring net losses, a growing accumulated deficit, and a 'going concern' warning. High dependence on a single customer and limited insurance coverage add substantial risk. The capital raise is for operational funding, not growth from a position of strength, and the stock trades on the OTC Pink Market, limiting investor appeal.

Positives

• Revenue for the three months ended September 30, 2025, increased by 125.30% to $390,164 compared to $173,174 in the prior year.
• Net loss for the three months ended September 30, 2025, decreased by 68.85% to $(61,598) from $(197,746) in the prior year.
• Revenue for the six months ended September 30, 2025, increased by 81.64% to $681,602 compared to $375,243 in the prior year.
• Net loss for the six months ended September 30, 2025, decreased by 52.64% to $(194,970) from $(411,654) in the prior year.
• Annual revenue for the year ended March 31, 2025, saw a substantial increase of 10806.76% to $817,898 from $7,499 in the prior year, driven by new PRC technical services.
• The company has expanded its operations into the Asia-Pacific and Chinese markets through its Dao Ling Doctor subsidiaries, which have demonstrated stronger revenue growth and higher-margin potential.
• Cash and cash equivalents increased to $455,446 as of September 30, 2025, from $370,549 as of March 31, 2025.
• Management is committed to implementing expense control measures to support liquidity.

Negatives

• The company has incurred recurring net losses, with a net loss of $(720,409) for the year ended March 31, 2025, an increase of 74.45% from the prior year.
• An accumulated deficit of $1,604,682 as of September 30, 2025, and $1,409,712 as of March 31, 2025, raises substantial doubt about the company's ability to continue as a going concern.
• Working capital decreased to $23,279 as of September 30, 2025, from $132,689 as of March 31, 2025.
• Gross margin decreased for both the three-month period (83.16% from 91.70%) and six-month period (82.04% from 96.13%) ended September 30, 2025, compared to the prior year, due to a shift in revenue streams to technical support and maintenance services with a different cost structure.
• Operating expenses for the year ended March 31, 2025, increased by 190.29% to $1,218,476, mainly due to increased rental expenses, employee wages and benefits, and start-up costs.
• 100% of the company's revenue and accounts receivable for the six months ended September 30, 2025, were derived from a single customer, posing a significant concentration risk.
• The company has limited insurance coverage, including no business interruption, product liability, directors and officers (D&O) liability, or key-man life insurance.
• The company's Common Stock is quoted on the Over The Counter Pink Market (OTC) and is subject to penny stock rules, which may limit liquidity and investor interest.
• The management team has limited experience in managing a publicly traded company and complying with associated complex laws and regulations.
• The company is dependent on its sole key executive, Barry Wan, who is not bound by an employment agreement.

Risks

• Limited operating history under the current business model and recent expansion into PRC technical-services and health-management markets makes it difficult to evaluate prospects.
• Difficulty raising additional capital, which could deprive the company of necessary resources and result in dilution to existing stockholders.
• Management team lacks experience in managing a public company and complying with applicable laws, potentially affecting business, financial conditions, and results of operations.
• Dependence on a single key executive (Barry Wan) who is not bound by an employment agreement and for whom the company does not maintain D&O liability insurance.
• Intense competition in both U.S. online advertising and PRC technical-services/health-management markets from established and emerging companies with greater resources.
• Failure to protect intellectual property (proprietary software, platform architecture, data, trade secrets, trademarks) could adversely affect the business.
• Inability to develop, maintain, or enhance the brand due to limited financial resources and low brand visibility, or negative publicity.
• Failure to achieve commercial acceptance of services to generate revenues and achieve profitability, as market demand may develop slowly or shift.
• Inability to successfully introduce new products and services or enhance existing ones due to technical challenges, regulatory considerations, or lack of resources.
• Consumer preferences for services are difficult to predict and may change, and failure to respond quickly to new trends could adversely affect the business.
• Failure to properly price products and services could have a material adverse effect on financial condition and results of operations.
• Inability to build and scale an effective sales and service delivery infrastructure to meet demand.
• Potential disputes relating to the use of third-party intellectual properties or intellectual property infringement claims by third parties.
• Adverse litigation judgments or settlements could expose the company to monetary damages or limit its ability to operate.
• Business may be materially adversely affected by new outbreaks or continuation of existing outbreaks of infectious diseases (e.g., COVID-19) and other disruptive events.
• Limited insurance coverage exposes the company to substantial costs and diversion of resources from accidents, business interruption, natural disasters, or other events.
• Risk of employee misconduct or other improper activities harming reputation and future prospects.
• Inability to renew existing leases on favorable terms may adversely affect results of operations.
• Common Stock is subject to penny stock rules of the SEC, and the trading market is limited, making transactions cumbersome and potentially reducing investment value.
• Trading on the Over the Counter Market is volatile and sporadic, which could depress the market price and make it difficult for holders to resell.
• Sales practice requirements of FINRA may limit a stockholder's ability to buy and sell Common Stock.
• Resale of shares covered by the Registration Statement could adversely affect the market price and ability to raise additional equity capital.
• Issuance of stock to fund operations may dilute investment and reduce equity interest.
• Trading price of Common Stock is likely to be volatile, potentially resulting in substantial losses to investors.
• If securities or industry analysts do not publish research or reports, or if they adversely change recommendations, market price and trading volume could decline.
• Negative publicity may harm brand and reputation.
• Operating results may fluctuate significantly or fall below expectations, causing stock price to fluctuate or decline.
• Enforceability of U.S. judgments against the company or its Chinese executive officers and directors in China is uncertain due to lack of treaties and PRC laws.

Future Outlook

The company plans to continue expanding its operations in both the U.S. online advertising platform and the PRC Dao Ling Doctor brand. In the PRC, management intends to develop standardized service stores, expand distributor-support systems, and integrate AI-based tools, including data-driven health-management functions and digital-human service features. Long-term goals include large-scale store expansion in both the PRC and U.S., broader non-medical health-management offerings, and exploration of new initiatives like cross-border duty-free retail and technology-driven community models (Web3/DAO). In the U.S., the focus remains on improving the online advertising and content-hosting platform to enhance user experience and strengthen customer retention.

Management Comments

• We believe these operational initiatives may enhance our long-term margins compared to reliance on the U.S. advertising business alone.
• We believe this one-stop service approach enhances customer experience and improves our ability to attract and retain potential clients.
• Management is committed to implementing expense control measures in the near term to support liquidity.
• Although our management team operates a relatively small organization and has limited experience managing a publicly traded company, we believe that their operational involvement and familiarity with our service lines support our ability to continue building our business.

Industry Context

Antiaging Quantum Living Inc. operates in two distinct, yet evolving, sectors: online advertising in the U.S. and technical services/non-medical health management in China. The U.S. online advertising market is highly competitive, dominated by large tech companies and numerous local providers, making it challenging for a small platform like dazhong368.com to gain significant market share. The expansion into China's health management and technical services market aligns with broader trends of digital health and platform-based service delivery, particularly in the Asia-Pacific region. However, this market is also competitive and subject to rapid technological changes and regulatory shifts. The company's strategy to integrate AI and expand its distributor network in China reflects an attempt to leverage technological advancements and a scalable business model to capture growth in these dynamic industries, moving away from its lower-margin U.S. advertising business.

Management Changes

Corporate Governance

Legal Proceedings

• There are no pending legal proceedings to which we are a party or in which any director, officer or affiliate of ours, any owner of record or beneficially of more than 5% of any class of our voting securities, or security holder is a party adverse to us or has a material interest adverse to us.

Related Party Transactions

• In August 2019, the company borrowed $71,000 from former President Mr. Dingshan Zhang. Additional loans of $5,000 (May 2021) and $24,300 (March 2023) were received. The total $83,300 shareholder loan was waived by Mr. Zhang on April 10, 2023, and recognized as an equity transaction.
• During the year ended March 31, 2024, the company received $613,843 in advances from Mr. Wan (CEO), which were unsecured, non-interest-bearing, and due on demand.
• On December 31, 2024, the company issued promissory notes totaling $1,667,701, including $428,789.50 to Mr. Barry Wan and $29,571.00 to New Lite Ventures LLC (controlled by Mr. Wan).
• On March 31, 2025, the company entered into Tripartite Debt Assignment Agreements, legally assigning $1,216,440 in notes and loans (originally from Hemeihui E-Commerce Co., Ltd. and Mr. Wan) to Mr. Barry Wan.
• During the six months ended September 30, 2025, the company received $340,000 in advances from Mr. Wan for working capital, bringing the total due to Mr. Wan to $860,000 as of September 30, 2025.
• Promissory notes payable and loans payable to related parties totaled $1,698,330 as of September 30, 2025, including amounts to Mr. Wan and New Lite Ventures LLC.
• On November 25, 2025, the promissory notes originally issued to Mr. Wan, New Lite Ventures LLC, and Hemeihui E-Commerce Co., Ltd. were assigned to third-party assignees (Atlantic Equity Holdings Inc. and Empire Street Capital Inc.) and then automatically converted into 4,280,340 shares of Class A Common Stock.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financings. Existing shares are restricted and subject to penny stock rules, limiting liquidity. The resale of 4.28 million shares could depress market price. The "going concern" warning indicates high risk of investment loss.
• Employees: The company has 3 full-time employees, all in PRC subsidiaries. Expansion plans may lead to more hiring, but the small management team and lack of key-man insurance for the CEO pose risks.
• Customers: Expansion of services and technical infrastructure in PRC aims to enhance customer experience and attract new clients. However, reliance on a single customer for 100% of recent revenue creates significant risk if that relationship is lost.
• Suppliers/Creditors: The company's reliance on related-party loans and short-term financing, along with the "going concern" doubt, could impact its ability to meet obligations to suppliers and creditors if additional funding is not secured.
• Management: High demands on the sole key executive, Barry Wan, who holds multiple critical roles and lacks an employment agreement or D&O insurance, creating personal and operational risk.

Next Steps

• Continue developing the Dao Ling Doctor ecosystem in the PRC through standardized service stores, expanded distributor-support systems, and integration of AI-based tools (data-driven health-management, digital-human service features).
• Explore additional service lines such as cross-border duty-free retail functions and technology-driven community models (Web3 or DAO-based membership concepts).
• Improve and maintain the U.S. online advertising and content-hosting platform, offering personalized ID card introduction pages and ongoing content-update support.
• Expand presence in additional geographic markets, including new provinces and municipalities in the PRC and a network of service locations in the United States.
• Hire additional managerial, technical, operational, and financial personnel to support growth.
• Implement expense control measures to support liquidity.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring net losses, a substantial and growing accumulated deficit, and an explicit 'going concern' warning from its auditors. While revenue growth from new PRC operations is positive, it has come with a significant increase in operating costs and a decline in gross margin percentage, indicating that profitability remains elusive. The extreme concentration risk, with 100% of recent revenue and accounts receivable tied to a single customer, makes the business highly vulnerable to a single point of failure. Furthermore, the company's limited insurance coverage, dependence on a single executive without an employment agreement or D&O insurance, and the illiquid trading environment on the OTC Pink Market (subject to penny stock rules) compound the risks. The current S-1 filing is for the resale of shares by selling stockholders, not a primary offering to raise capital for the company, meaning no new funds are flowing into the company from this registration. Given these fundamental weaknesses and high operational and financial risks, the stock represents a strong sell for any seasoned investor or institution.

Keywords

Antiaging Quantum Living Inc., AAQL, SEC S-1, Registration Statement, Online Advertising, Dao Ling Doctor, Health Management, Technical Services, China Market, PRC Operations, OTC Pink Market, Promissory Notes, Debt Conversion, Share Resale, Going Concern, Related Party Transactions, Concentration Risk, Emerging Growth Company, Barry Wan, New York, Flushing, Hangzhou, Zhejiang